Engineered responsive-hydrogels drive cGAS-STING pathway activation for cancer immunotherapy

Area of Science:

• Immunology
• Biomaterials Science
• Cancer Therapy

Background:

• The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway is a promising target for cancer immunotherapy.
• Clinical application is limited by a narrow therapeutic window and risk of systemic inflammation, necessitating precise activation strategies.

Purpose of the Study:

• To review the immunological basis and therapeutic window for cGAS-STING activation in cancer.
• To survey hydrogel engineering strategies for controlled spatiotemporal immune activation within the tumor microenvironment.
• To examine hydrogel-enabled combination therapies with temporal programming for enhanced cancer immunotherapy.

Main Methods:

• Review of existing literature on cGAS-STING pathway immunology and hydrogel engineering.
• Analysis of hydrogel strategies including cargo loading, affinity-based retention, and stimuli-responsive release.
• Examination of temporal programming and staged activation in hydrogel-based combination regimens.

Main Results:

• Engineered hydrogels act as injectable depots for sustained, localized delivery within the tumor microenvironment.
• Hydrogel strategies allow coupling of release kinetics with spatiotemporal immune activation profiles.
• Hydrogel platforms facilitate combinational regimens with temporal programming for staged immune activation.

Conclusions:

• Hydrogel platforms offer a viable strategy to bridge controlled release with immune microenvironment remodeling for cancer immunotherapy.
• Technological refinement, manufacturing considerations, and regulatory alignment are crucial for clinical translation.
• Precision activation of the cGAS-STING pathway using hydrogels holds significant potential for advancing cancer immunotherapy.